Last reviewed · How we verify
NCT04905225
The Gender Specific Effect on the Results of Ascending Aortic Replacement
trial testing Ascending aortic replacement in Ascending Aortic Aneurysm in 200 participants. Completed in 1 July 2023.
1 June 2022
Quick facts
| Lead sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2013 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 July 2023 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Ascending aortic replacement
Conditions studied
- Ascending Aortic Aneurysm — all drugs for Ascending Aortic Aneurysm →
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Who can join
Adults 18 to 80, any sex, with Ascending Aortic Aneurysm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study is to analyze the early and late results in men and women who underwent ascending aortic replacement in antegrade cerebral perfusion (ACP) with mild-to-moderate hypothermic circulatory arrest. Female gender is associated with poorer outcomes after surgical aorta replacement. Data on gender specific differences after ascending aortic replacement are conflicting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04905225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ascending Aortic Aneurysm
Currently open trials in the same condition.
- NCT06377449 — Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients · NA · recruiting
- NCT07034586 — Prospective Evaluation of Adventitial Histopathology in Borderline Ascending Aortic Dilatatio · active not recruiting
- NCT03440697 — Pathogenetic Basis of Aortopathy and Aortic Valve Disease · active not recruiting
Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials
Trials by the same sponsor.
- NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
- NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
- NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
- NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
- NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04905225 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04905225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing